CONTEXT: There has been rapid adoption of newer radiation treatments such as intensity-modulated radiation therapy (IMRT) and proton therapy despite greater cost and limited demonstrated benefit compared with previous technologies. OBJECTIVE: To determine the comparative morbidity and disease control of IMRT, proton therapy, and conformal radiation therapy for primary prostate cancer treatment. DESIGN, SETTING, AND PATIENTS: Population-based study using Surveillance, Epidemiology, and End Results-Medicare-linked data from 2000 through 2009 for patients with nonmetastatic prostate cancer. MAIN OUTCOME MEASURES: Rates of gastrointestinal and urinary morbidity, erectile dysfunction, hip fractures, and additional cancer therapy. RESULTS: Use of IMRT vs conformal radiation therapy increased from 0.15% in 2000 to 95.9% in 2008. In propensity score-adjusted analyses (N = 12,976), men who received IMRT vs conformal radiation therapy were less likely to receive a diagnosis of gastrointestinal morbidities (absolute risk, 13.4 vs 14.7 per 100 person-years; relative risk [RR], 0.91; 95% CI, 0.86-0.96) and hip fractures (absolute risk, 0.8 vs 1.0 per 100 person-years; RR, 0.78; 95% CI, 0.65-0.93) but more likely to receive a diagnosis of erectile dysfunction (absolute risk, 5.9 vs 5.3 per 100 person-years; RR, 1.12; 95% CI, 1.03-1.20). Intensity-modulated radiation therapy patients were less likely to receive additional cancer therapy (absolute risk, 2.5 vs 3.1 per 100 person-years; RR, 0.81; 95% CI, 0.73-0.89). In a propensity score-matched comparison between IMRT and proton therapy (n = 1368), IMRT patients had a lower rate of gastrointestinal morbidity (absolute risk, 12.2 vs 17.8 per 100 person-years; RR, 0.66; 95% CI, 0.55-0.79). There were no significant differences in rates of other morbidities or additional therapies between IMRT and proton therapy. CONCLUSIONS: Among patients with nonmetastatic prostate cancer, the use of IMRT compared with conformal radiation therapy was associated with less gastrointestinal morbidity and fewer hip fractures but more erectile dysfunction; IMRT compared with proton therapy was associated with less gastrointestinal morbidity.
CONTEXT: There has been rapid adoption of newer radiation treatments such as intensity-modulated radiation therapy (IMRT) and proton therapy despite greater cost and limited demonstrated benefit compared with previous technologies. OBJECTIVE: To determine the comparative morbidity and disease control of IMRT, proton therapy, and conformal radiation therapy for primary prostate cancer treatment. DESIGN, SETTING, AND PATIENTS: Population-based study using Surveillance, Epidemiology, and End Results-Medicare-linked data from 2000 through 2009 for patients with nonmetastatic prostate cancer. MAIN OUTCOME MEASURES: Rates of gastrointestinal and urinary morbidity, erectile dysfunction, hip fractures, and additional cancer therapy. RESULTS: Use of IMRT vs conformal radiation therapy increased from 0.15% in 2000 to 95.9% in 2008. In propensity score-adjusted analyses (N = 12,976), men who received IMRT vs conformal radiation therapy were less likely to receive a diagnosis of gastrointestinal morbidities (absolute risk, 13.4 vs 14.7 per 100 person-years; relative risk [RR], 0.91; 95% CI, 0.86-0.96) and hip fractures (absolute risk, 0.8 vs 1.0 per 100 person-years; RR, 0.78; 95% CI, 0.65-0.93) but more likely to receive a diagnosis of erectile dysfunction (absolute risk, 5.9 vs 5.3 per 100 person-years; RR, 1.12; 95% CI, 1.03-1.20). Intensity-modulated radiation therapy patients were less likely to receive additional cancer therapy (absolute risk, 2.5 vs 3.1 per 100 person-years; RR, 0.81; 95% CI, 0.73-0.89). In a propensity score-matched comparison between IMRT and proton therapy (n = 1368), IMRT patients had a lower rate of gastrointestinal morbidity (absolute risk, 12.2 vs 17.8 per 100 person-years; RR, 0.66; 95% CI, 0.55-0.79). There were no significant differences in rates of other morbidities or additional therapies between IMRT and proton therapy. CONCLUSIONS: Among patients with nonmetastatic prostate cancer, the use of IMRT compared with conformal radiation therapy was associated with less gastrointestinal morbidity and fewer hip fractures but more erectile dysfunction; IMRT compared with proton therapy was associated with less gastrointestinal morbidity.
Authors: C M Nutting; D J Convery; V P Cosgrove; C Rowbottom; A R Padhani; S Webb; D P Dearnaley Journal: Int J Radiat Oncol Biol Phys Date: 2000-10-01 Impact factor: 7.038
Authors: A Pollack; G K Zagars; L G Smith; J J Lee; A C von Eschenbach; J A Antolak; G Starkschall; I Rosen Journal: J Clin Oncol Date: 2000-12-01 Impact factor: 44.544
Authors: Sean P Elliott; Stephanie L Jarosek; Shaheen R Alanee; Badrinath R Konety; Kathryn E Dusenbery; Beth A Virnig Journal: Cancer Date: 2011-03-16 Impact factor: 6.860
Authors: Alan Pollack; Gunar K Zagars; George Starkschall; John A Antolak; J Jack Lee; Eugene Huang; Andrew C von Eschenbach; Deborah A Kuban; Isaac Rosen Journal: Int J Radiat Oncol Biol Phys Date: 2002-08-01 Impact factor: 7.038
Authors: Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei Journal: N Engl J Med Date: 2008-03-20 Impact factor: 91.245
Authors: Arnold L Potosky; Joan L Warren; Elyn R Riedel; Carrie N Klabunde; Craig C Earle; Colin B Begg Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Nicholas G Zaorsky; Amy S Harrison; Edouard J Trabulsi; Leonard G Gomella; Timothy N Showalter; Mark D Hurwitz; Adam P Dicker; Robert B Den Journal: Nat Rev Urol Date: 2013-09-10 Impact factor: 14.432
Authors: Chad Tang; Xiudong Lei; Grace L Smith; Hubert Y Pan; Kenneth Hess; Aileen Chen; Karen E Hoffman; Brian F Chapin; Deborah A Kuban; Mitchell Anscher; Ya-Chen Tina Shih; Steven J Frank; Benjamin D Smith Journal: Pract Radiat Oncol Date: 2020-04-13
Authors: Samhita Chakraborty; Monica M Morris; Todd W Bauer; Reid B Adams; Edward B Stelow; Gina Petroni; Hanna K Sanoff Journal: Gastrointest Cancer Res Date: 2014-01
Authors: Joseph C Cheng; Aiping Bai; Thomas H Beckham; S Tucker Marrison; Caroline L Yount; Katherine Young; Ping Lu; Anne M Bartlett; Bill X Wu; Barry J Keane; Kent E Armeson; David T Marshall; Thomas E Keane; Michael T Smith; E Ellen Jones; Richard R Drake; Alicja Bielawska; James S Norris; Xiang Liu Journal: J Clin Invest Date: 2013-09-16 Impact factor: 14.808
Authors: Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair Journal: Antioxid Redox Signal Date: 2014-01-22 Impact factor: 8.401
Authors: Nicholas G Zaorsky; Nitin Ohri; Timothy N Showalter; Adam P Dicker; Robert B Den Journal: Cancer Treat Rev Date: 2013-03-01 Impact factor: 12.111
Authors: James B Yu; Pamela R Soulos; Jeph Herrin; Laura D Cramer; Arnold L Potosky; Kenneth B Roberts; Cary P Gross Journal: J Natl Cancer Inst Date: 2012-12-14 Impact factor: 13.506